Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Kranthi Kumar Chougoni, Victoria Neely, Boxiao Ding, Eziafa Oduah, Vianna T. Lam, Bin Hu, Jennifer E. Koblinski, Bradford E. Windle, Swati Palit Deb, Sumitra Deb, Jorge J. Nieva, Senthil K. Radhakrishnan, Hisashi Harada, Steven R. GrossmanCancer 2024 · DOI

TL;DR

Oncogenic mutant p53 (Onc-p53) in non-small cell lung cancer (NSCLC) creates a vulnerability to proteasome inhibitors (PIs) by inducing oxidative stress. This stress triggers a cascade leading to apoptosis, suggesting a novel therapeutic strategy combining PIs with BH3-mimetics and chemotherapy for NSCLC patients with Onc-p53 mutations.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related death, largely due to limited effective therapies for advanced disease. While proteasome inhibitors (PIs) are successful in certain blood cancers (like multiple myeloma), their efficacy in solid tumors like NSCLC has been modest. This paper investigates why and how PIs might be repurposed for NSCLC, focusing on a specific genetic alteration: oncogenic mutant p53 (Onc-p53). Onc-p53 is prevalent in NSCLC and is known to confer "gain-of-function" properties, potentially creating unique vulnerabilities. The authors hypothesize that Onc-p53 might sensitize NSCLC cells to PIs, and they aim to elucidate the underlying molecular mechanisms to develop more effective treatment strategies.

Methods

The researchers employed a multi-pronged approach:

  • Cell Line Studies: They utilized various NSCLC cell lines with different p53 statuses (wild-type vs. oncogenic mutant) to assess proteasome activity, sensitivity to PIs (bortezomib - BTZ, carfilzomib - CFZ), and cellular responses.
  • Molecular Assays: Standard techniques like Western blotting, qRT-PCR, and flow cytometry were used to measure protein and mRNA expression, ROS levels, glutathione levels, and apoptosis markers (Annexin V, cleaved caspase-3).
  • Genetic Manipulation: CRISPR/Cas9 was used to create p53 knockout cell lines, and shRNA was employed to knock down specific genes (NOXA, NRF2, ATF3) to determine their necessity in the observed pathways.
  • Immunofluorescence: This technique was used to visualize the subcellular localization of proteins, specifically NRF2, to understand its translocation upon treatment.
  • In Vivo Xenograft Models: Mouse models bearing human NSCLC tumors were used to test the efficacy of combination therapies in a more complex biological system.
  • Metabolomic Profiling: This was used to assess cellular metabolite levels, specifically glutathione.

Datasets

Not explicitly discussed as distinct datasets for training/evaluation in the machine learning sense. The study relies on established NSCLC cell lines and their characterized p53 mutational status. Metabolomic data from the DepMap project was mined to assess glutathione levels in a larger cohort of NSCLC cell lines.

Key Insights and Ideas

  • Onc-p53 as a PI Vulnerability Driver: The presence of oncogenic mutant p53, not just the absence of wild-type p53, is the key factor sensitizing NSCLC cells to proteasome inhibitors.
  • Oxidative Stress is Central: Bortezomib's cytotoxic effect in Onc-p53 NSCLC cells is critically dependent on oxidative stress. Blocking this stress with antioxidants abrogates the drug's efficacy.
  • NRF2-ATF3-NOXA Cascade: Onc-p53 NSCLC cells treated with BTZ exhibit a specific signaling pathway: oxidative stress leads to NRF2 nuclear translocation, which in turn induces ATF3, ultimately upregulating the pro-apoptotic protein NOXA.
  • Apoptosis as the Mechanism: The cell death induced by BTZ in these cells is primarily apoptotic, mediated by the NOXA-driven pathway.
  • Translational Potential: The findings strongly suggest that combining PIs with BH3-mimetics (which target anti-apoptotic proteins) and standard chemotherapy could be a potent precision therapy for NSCLC patients with Onc-p53 mutations.

Key Results

  • Onc-p53 NSCLC cells showed 6- to 15-fold lower IC50 values for bortezomib (BTZ) compared to wild-type p53 cells.
  • BTZ treatment significantly increased ROS levels in Onc-p53 cells but not in wild-type p53 cells.
  • Antioxidants (NAC, GSH-EE) abrogated BTZ-induced cell death in Onc-p53 NSCLC cells.
  • BTZ induced NOXA mRNA and protein expression in Onc-p53 cells, which was dependent on ATF3.
  • NRF2 was shown to translocate to the nucleus upon BTZ treatment, and its knockdown rendered cells resistant to BTZ.
  • Knocking down NRF2 or ATF3 significantly reduced BTZ-induced NOXA expression and apoptosis.
  • A combination of BTZ and the BH3-mimetic navitoclax showed synergistic cytotoxicity in vitro and significantly reduced tumor growth in vivo in Onc-p53 NSCLC xenografts, but not in wild-type p53 xenografts.

Limitations and Future Work

  • Source of ROS: The exact source of both basal and PI-induced ROS in Onc-p53 cells remains unclear and warrants further investigation. Potential sources include GSH depletion or direct oxidative activity related to Onc-p53 or upregulated proteasomes.
  • NRF2 Regulation Complexity: While the study demonstrates NRF2's role, the precise mechanism of its regulation (e.g., KEAP1 dissociation vs. direct interaction with Onc-p53) requires further detailed study.
  • Navitoclax Toxicity: The authors acknowledge the clinical limitations of navitoclax due to thrombocytopenia. They suggest that next-generation BH3-mimetics (like WH244 or pelcitoclax) could serve as suitable replacements for future clinical trials.
  • Carboplatin's Role: The specific contribution of carboplatin to the observed combination therapy efficacy was not fully elucidated, though it's noted that platinum agents can increase oxidative stress.
  • Broader Applicability: While the study focuses on NSCLC, the authors suggest that this PI sensitivity mechanism might extend to other cancers with high frequencies of Onc-p53 mutations (e.g., small cell lung cancer, ovarian, pancreatic).
  • Clinical Translation: The paper strongly advocates for clinical trials to test PI/BH3-mimetic/chemotherapy combinations in patients with Onc-p53-expressing NSCLC, emphasizing the need for biomarker-driven patient selection.

Summary updated

Abstract

NSCLC is the leading cause of cancer death due, in part, to a lack of active therapies in advanced disease. We demonstrate that combination therapy with a proteasome inhibitor, BH3-mimetic, and chemotherapy is an active precision therapy in NSCLC cells and tumors expressing Onc-p53 alleles.
BibTeX
@inproceedings{chougoni2024oncogenic,
  author = {Kranthi Kumar Chougoni and Victoria Neely and Boxiao Ding and Eziafa Oduah and Vianna T. Lam and Bin Hu and Jennifer E. Koblinski and Bradford E. Windle and Swati Palit Deb and Sumitra Deb and Jorge J. Nieva and Senthil K. Radhakrishnan and Hisashi Harada and Steven R. Grossman},
  title = {{Oncogenic Mutant <i>p53</i> Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1158/2767-9764.crc-23-0637},
}
Figure